全文获取类型
收费全文 | 1167624篇 |
免费 | 78192篇 |
国内免费 | 1708篇 |
专业分类
耳鼻咽喉 | 16044篇 |
儿科学 | 36934篇 |
妇产科学 | 30095篇 |
基础医学 | 166374篇 |
口腔科学 | 31663篇 |
临床医学 | 104437篇 |
内科学 | 222969篇 |
皮肤病学 | 26035篇 |
神经病学 | 91349篇 |
特种医学 | 46708篇 |
外国民族医学 | 207篇 |
外科学 | 176233篇 |
综合类 | 22831篇 |
现状与发展 | 1篇 |
一般理论 | 330篇 |
预防医学 | 81926篇 |
眼科学 | 26147篇 |
药学 | 92308篇 |
7篇 | |
中国医学 | 2909篇 |
肿瘤学 | 72017篇 |
出版年
2021年 | 9477篇 |
2019年 | 9516篇 |
2018年 | 13445篇 |
2017年 | 10507篇 |
2016年 | 12015篇 |
2015年 | 13474篇 |
2014年 | 18209篇 |
2013年 | 26084篇 |
2012年 | 36532篇 |
2011年 | 38362篇 |
2010年 | 22556篇 |
2009年 | 21127篇 |
2008年 | 35324篇 |
2007年 | 37903篇 |
2006年 | 38174篇 |
2005年 | 36414篇 |
2004年 | 34812篇 |
2003年 | 33087篇 |
2002年 | 31978篇 |
2001年 | 61591篇 |
2000年 | 62929篇 |
1999年 | 52340篇 |
1998年 | 13557篇 |
1997年 | 11915篇 |
1996年 | 11753篇 |
1995年 | 11059篇 |
1994年 | 9962篇 |
1993年 | 9442篇 |
1992年 | 38759篇 |
1991年 | 37196篇 |
1990年 | 36607篇 |
1989年 | 35128篇 |
1988年 | 31609篇 |
1987年 | 30703篇 |
1986年 | 28933篇 |
1985年 | 27168篇 |
1984年 | 19778篇 |
1983年 | 16619篇 |
1982年 | 9332篇 |
1979年 | 17493篇 |
1978年 | 11772篇 |
1977年 | 10562篇 |
1976年 | 9102篇 |
1975年 | 10361篇 |
1974年 | 11985篇 |
1973年 | 11591篇 |
1972年 | 11037篇 |
1971年 | 10321篇 |
1970年 | 9514篇 |
1969年 | 9182篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Xiaoyan Lu Isabelle R. Miousse Sandra V. Pirela Jodene K. Moore Stepan Melnyk 《Nanotoxicology》2016,10(5):629-639
Evidence continues to grow on potential environmental health hazards associated with engineered nanomaterials (ENMs). While the geno- and cytotoxic effects of ENMs have been investigated, their potential to target the epigenome remains largely unknown. The aim of this study is two-fold: 1) determining whether or not industry relevant ENMs can affect the epigenome in vivo and 2) validating a recently developed in vitro epigenetic screening platform for inhaled ENMs. Laser printer-emitted engineered nanoparticles (PEPs) released from nano-enabled toners during consumer use and copper oxide (CuO) were chosen since these particles induced significant epigenetic changes in a recent in vitro companion study. In this study, the epigenetic alterations in lung tissue, alveolar macrophages and peripheral blood from intratracheally instilled mice were evaluated. The methylation of global DNA and transposable elements (TEs), the expression of the DNA methylation machinery and TEs, in addition to general toxicological effects in the lung were assessed. CuO exhibited higher cell-damaging potential to the lung, while PEPs showed a greater ability to target the epigenome. Alterations in the methylation status of global DNA and TEs, and expression of TEs and DNA machinery in mouse lung were observed after exposure to CuO and PEPs. Additionally, epigenetic changes were detected in the peripheral blood after PEPs exposure. Altogether, CuO and PEPs can induce epigenetic alterations in a mouse experimental model, which in turn confirms that the recently developed in vitro epigenetic platform using macrophage and epithelial cell lines can be successfully utilized in the epigenetic screening of ENMs. 相似文献
12.
13.
14.
15.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
16.
Martin F. Shapiro 《Journal of general internal medicine》2015,30(10):1392-1393
17.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
18.
Harit Kapoor Kush Raj Lohani Tommy H. Lee Devendra K. Agrawal Sumeet K. Mittal 《CTS Clinical and Translational Science》2015,8(6):841-847
Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long‐standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5‐year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett''s esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett''s esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett''s esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett''s carcinogenesis. 相似文献
19.
20.